Shares surged to an all-time high of $281.69 on May 29 as investors piled in ahead of tomorrow's fiscal Q3 report, capping a 70%-plus rally since late March. The catalyst: a freshly exploited flaw in the company's widely used remote-access VPN software that has forced governments and corporations into emergency patching — and reminded the market why cybersecurity spending is non-negotiable.

A VPN Bug Becomes a Buying Signal

Authentication bypass vulnerabilities (CVE-2026-0257) in Palo Alto's firewalls, disclosed May 13, have been targeted in "limited exploit attempts."

Rapid7 confirmed exploitation across numerous customers starting May 17 , and Palo Alto raised the severity rating to High after active attacks were confirmed, prompting CISA to order federal agencies to patch by June 1. Paradoxically, a bug in Palo Alto's own product spotlights the urgency of its market — every breach headline accelerates enterprise security budgets.

Wall Street Is Betting Big on the Earnings Print

Palo Alto is scheduled to report Q3 results on June 2, with analysts estimating EPS of $0.72 and revenue of $2.94 billion.

Management guided Q3 revenue to $2.941–$2.945 billion, up 28–29% year-over-year, with non-GAAP EPS of $0.78–$0.80.

The company has beaten EPS estimates in eight consecutive quarters. The options market is pricing roughly an 8% post-earnings swing — meaning tomorrow's call could either validate or erase the recent rally in a single session.

Acquisitions Add Revenue but Dilute Earnings

Palo Alto issued 112 million shares for its CyberArk acquisition in Q2, creating significant dilution that weighs on per-share profits.

Full-year EPS guidance was cut to $3.65–$3.70, down from prior guidance of $3.80–$3.90. The M&A spree — CyberArk, Chronosphere, and two smaller AI security deals — brings growth but forces investors to trust that cross-selling will pay off before the dilution drag becomes a problem.

Valuation Leaves No Room for a Miss

At $281.69, PANW trades at roughly 76 times trailing earnings and 20 times sales, with a market cap of $228.45 billion.

The stock's 52-week range spans from $139.57 to $283.71 , meaning it sits at the absolute ceiling. The average analyst 12-month price target is $230.82 — actually below the current price — though 44 of 54 analysts still rate it a Buy. If Q3 numbers or guidance disappoint even modestly, the gap between where the stock trades and where analysts think it belongs could close violently to the downside.